This development is part of Botanix’s strategy to expand payer coverage, now reaching over 110 million commercial lives, for its novel treatment targeting primary axillary hyperhidrosis, a condition ...
The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback